NASDAQ:DEPO - Depomed Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.34 -0.40 (-5.93 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$6.34
Today's Range$6.28 - $6.75
52-Week Range$4.31 - $11.27
Volume841,349 shs
Average Volume1.29 million shs
Market Capitalization$426.04 million
P/E Ratio-5.03
Dividend YieldN/A
Beta1.22

About Depomed (NASDAQ:DEPO)

Depomed logoDepomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. Depomed, Inc. has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc.; and a license agreement with Janssen Pharmaceuticals, Inc. based on its proprietary Acuform gastroretentive drug delivery technology. The company sells its products to wholesalers and retail pharmacies. Depomed, Inc. was founded in 1995 and is headquartered in Newark, California.

Receive DEPO News and Ratings via Email

Sign-up to receive the latest news and ratings for DEPO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:DEPO
CUSIP24990810
Phone510-744-8000

Debt

Debt-to-Equity Ratio2.55
Current Ratio0.75
Quick Ratio0.73

Price-To-Earnings

Trailing P/E Ratio-5.03
Forward P/E Ratio-5.76
P/E GrowthN/A

Sales & Book Value

Annual Sales$380.72 million
Price / Sales1.06
Cash Flow$0.7915 per share
Price / Cash8.01
Book Value$3.24 per share
Price / Book1.96

Profitability

EPS (Most Recent Fiscal Year)($1.26)
Net Income$-102,490,000.00
Net Margins-10.02%
Return on Equity-15.74%
Return on Assets-2.95%

Miscellaneous

Employees434
Outstanding Shares63,590,000

Depomed (NASDAQ:DEPO) Frequently Asked Questions

What is Depomed's stock symbol?

Depomed trades on the NASDAQ under the ticker symbol "DEPO."

How were Depomed's earnings last quarter?

Depomed Inc (NASDAQ:DEPO) announced its earnings results on Thursday, May, 10th. The specialty pharmaceutical company reported $0.28 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.41) by $0.69. The specialty pharmaceutical company earned $128.40 million during the quarter, compared to analyst estimates of $65.77 million. Depomed had a negative net margin of 10.02% and a negative return on equity of 15.74%. Depomed's revenue was up 41.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.07 earnings per share. View Depomed's Earnings History.

When is Depomed's next earnings date?

Depomed is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Depomed.

What price target have analysts set for DEPO?

7 analysts have issued 1 year price objectives for Depomed's shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate Depomed's stock price to reach $8.00 in the next twelve months. View Analyst Ratings for Depomed.

Who are some of Depomed's key competitors?

Who are Depomed's key executives?

Depomed's management team includes the folowing people:
  • Mr. Arthur Joseph Higgins, CEO, Pres & Director (Age 62)
  • Mr. August J. Moretti, CFO & Sr. VP (Age 67)
  • Mr. Matthew M. Gosling, Sr. VP, Gen. Counsel & Sec. (Age 47)
  • Mr. Sean P. McKercher, Sr. VP of Operations & Bus. (Age 61)
  • Dr. Stan Bukofzer, Sr. VP and Chief Medical & Scientific Officer (Age 62)

Has Depomed been receiving favorable news coverage?

News headlines about DEPO stock have trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Depomed earned a coverage optimism score of 0.19 on Accern's scale. They also gave media stories about the specialty pharmaceutical company an impact score of 45.52 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Depomed's major shareholders?

Depomed's stock is owned by a variety of of retail and institutional investors. Top institutional investors include STARBOARD VALUE LP (7.70%), STARBOARD VALUE LP (6.10%), Dimensional Fund Advisors LP (5.21%), STARBOARD VALUE LP (4.30%), Prudential Financial Inc. (1.87%) and Millennium Management LLC (1.68%). Company insiders that own Depomed stock include Arthur J Higgins, August J Moretti, Matthew M Gosling and Thadd M Vargas. View Institutional Ownership Trends for Depomed.

Which major investors are selling Depomed stock?

DEPO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, State of Wisconsin Investment Board, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp, Deltec Asset Management LLC, GSA Capital Partners LLP, Schwab Charles Investment Management Inc., Systematic Financial Management LP and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Depomed.

Which major investors are buying Depomed stock?

DEPO stock was purchased by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Opaleye Management Inc., Dimensional Fund Advisors LP, Massachusetts Financial Services Co. MA, Redwood Investment Management LLC, Hsbc Holdings PLC, Engineers Gate Manager LP and Mackay Shields LLC. View Insider Buying and Selling for Depomed.

How do I buy shares of Depomed?

Shares of DEPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Depomed's stock price today?

One share of DEPO stock can currently be purchased for approximately $6.34.

How big of a company is Depomed?

Depomed has a market capitalization of $426.04 million and generates $380.72 million in revenue each year. The specialty pharmaceutical company earns $-102,490,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Depomed employs 434 workers across the globe.

How can I contact Depomed?

Depomed's mailing address is 7999 GATEWAY BLVD. SUITE 300, NEWARK CA, 94560. The specialty pharmaceutical company can be reached via phone at 510-744-8000 or via email at [email protected]


MarketBeat Community Rating for Depomed (DEPO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  418 (Vote Outperform)
Underperform Votes:  306 (Vote Underperform)
Total Votes:  724
MarketBeat's community ratings are surveys of what our community members think about Depomed and other stocks. Vote "Outperform" if you believe DEPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DEPO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Depomed (NASDAQ:DEPO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Depomed in the last 12 months. Their average twelve-month price target is $8.00, suggesting that the stock has a possible upside of 26.18%. The high price target for DEPO is $10.00 and the low price target for DEPO is $5.00. There are currently 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.292.252.252.22
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.00$8.75$9.6250$10.1111
Price Target Upside: 26.18% upside34.41% upside15.55% upside57.49% upside

Depomed (NASDAQ:DEPO) Consensus Price Target History

Price Target History for Depomed (NASDAQ:DEPO)

Depomed (NASDAQ:DEPO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/23/2018MizuhoReiterated RatingBuy$9.00HighView Rating Details
3/2/2018Roth CapitalSet Price TargetBuy$10.00MediumView Rating Details
3/1/2018Piper Jaffray CompaniesReiterated RatingHold$8.00MediumView Rating Details
12/7/2017Royal Bank of CanadaSet Price TargetHold$9.00MediumView Rating Details
11/10/2017UBSBoost Price TargetNeutral$6.00 ➝ $7.00N/AView Rating Details
11/9/2017Morgan StanleyUpgradeUnderweight ➝ Equal WeightN/AView Rating Details
8/8/2017Janney Montgomery ScottDowngradeBuy ➝ Neutral$18.00 ➝ $8.00HighView Rating Details
5/15/2017Cantor FitzgeraldSet Price TargetHold$14.00MediumView Rating Details
3/30/2017JMP SecuritiesReiterated RatingOutperform$30.00 ➝ $16.00HighView Rating Details
11/8/2016Leerink SwannSet Price TargetBuy$22.00N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Depomed (NASDAQ:DEPO) Earnings History and Estimates Chart

Earnings by Quarter for Depomed (NASDAQ:DEPO)

Depomed (NASDAQ:DEPO) Earnings Estimates

2018 EPS Consensus Estimate: $0.38
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.03$0.03$0.03
Q2 20181$0.09$0.09$0.09
Q3 20181$0.12$0.12$0.12
Q4 20181$0.14$0.14$0.14

Depomed (NASDAQ DEPO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018$0.16N/AView Earnings Details
5/10/2018Q1 2018($0.41)$0.28$65.77 million$128.40 millionViewN/AView Earnings Details
2/27/2018Q4 2017$0.10$0.15$88.75 million$94.41 millionViewListenView Earnings Details
11/7/2017Q3 2017$0.12$0.14$99.11 million$95.40 millionViewN/AView Earnings Details
8/7/2017Q2 2017$0.09($0.43)$100.40 million$100.00 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.25)($0.43)$99.48 million$95.00 millionViewListenView Earnings Details
2/21/2017Q4 2016$0.3550$0.48$123.00 million$123.90 millionViewListenView Earnings Details
11/7/2016Q3$0.35$0.28$127.22 million$111.00 millionViewListenView Earnings Details
8/3/2016Q2$0.26$0.27$118.20 million$116.70 millionViewListenView Earnings Details
5/5/2016Q1$0.17$0.12$106.88 million$104.60 millionViewListenView Earnings Details
2/22/2016Q415$0.29$0.16$110.19 million$111.20 millionViewListenView Earnings Details
11/9/2015Q3$0.19$0.33$101.64 million$105.00 millionViewListenView Earnings Details
7/29/2015Q215($0.45)$0.27$88.33 million$94.30 millionViewListenView Earnings Details
5/11/2015Q115$0.07($0.13)$33.80 million$31.70 millionViewListenView Earnings Details
2/23/2015Q414$0.07$0.21$44.66 million$33.90 millionViewListenView Earnings Details
11/5/2014Q314($0.04)($0.01)$41.50 million$51.49 millionViewListenView Earnings Details
8/6/2014Q214($0.06)($0.03)$38.03 million$67.70 millionViewListenView Earnings Details
5/8/2014Q114$0.11($0.04)$53.57 million$76.50 millionViewListenView Earnings Details
3/12/2014Q413($0.21)$0.72$19.06 million$40.60 millionViewListenView Earnings Details
11/5/2013Q313$0.07$0.11$35.55 million$37.50 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.05)$0.01$29.87 million$30.00 millionViewListenView Earnings Details
5/8/2013Q1 2013($0.06)($0.10)$28.93 million$26.20 millionViewListenView Earnings Details
2/20/2013Q4 2012($0.11)($0.07)$26.48 million$26.60 millionViewListenView Earnings Details
11/5/2012Q312($0.11)($0.03)$28.06 million$33.30 millionViewN/AView Earnings Details
8/2/2012($0.22)($0.28)ViewN/AView Earnings Details
5/8/2012($0.24)($0.16)ViewN/AView Earnings Details
3/8/2012($0.31)($0.25)ViewN/AView Earnings Details
11/1/2011($0.23)($0.15)ViewN/AView Earnings Details
8/1/2011($0.05)($0.11)ViewN/AView Earnings Details
5/5/2011$1.05$1.77ViewN/AView Earnings Details
3/3/2011$0.06$0.03ViewN/AView Earnings Details
11/1/2010Q3 2010($0.02)$0.04ViewN/AView Earnings Details
8/5/2010Q2 2010$0.04$0.08ViewN/AView Earnings Details
4/29/2010Q1 2010($0.07)($0.07)ViewN/AView Earnings Details
3/4/2010Q4 2009($0.13)($0.07)ViewN/AView Earnings Details
10/29/2009Q3 2009($0.06)($0.10)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.19)($0.19)ViewN/AView Earnings Details
5/4/2009Q1 2009($0.22)($0.20)ViewN/AView Earnings Details
3/5/2009Q4 2008($0.26)($0.22)ViewN/AView Earnings Details
10/30/2008Q3 2008($0.15)($0.12)ViewN/AView Earnings Details
7/31/2008Q2 2008($0.22)($0.03)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.16)ViewN/AView Earnings Details
3/6/2008Q4 2007$0.40$0.44ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Depomed (NASDAQ:DEPO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Depomed (NASDAQ DEPO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.27%
Institutional Ownership Percentage: 97.36%
Insider Trading History for Depomed (NASDAQ:DEPO)
Institutional Ownership by Quarter for Depomed (NASDAQ:DEPO)

Depomed (NASDAQ DEPO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/11/2018Matthew M. GoslingSVPSell19,674$7.07$139,095.18View SEC Filing  
3/7/2018Matthew M. GoslingSVPSell45,519$6.58$299,515.02View SEC Filing  
12/14/2017Arthur J. HigginsInsiderBuy75,000$8.16$612,000.00View SEC Filing  
6/12/2017Arthur J HigginsInsiderBuy15,000$9.92$148,800.00View SEC Filing  
11/14/2016August J MorettiCFOSell5,000$20.84$104,200.0026,680View SEC Filing  
9/21/2016Thadd M VargasVPSell11,250$25.00$281,250.0073,086View SEC Filing  
8/10/2016August J. MorettiCFOSell5,000$21.40$107,000.00View SEC Filing  
8/10/2016Thadd M VargasVPSell26,290$20.92$549,986.8084,336View SEC Filing  
5/23/2016Thadd M VargasVPSell15,000$20.00$300,000.00109,297View SEC Filing  
5/10/2016Thadd M VargasVPSell15,000$17.64$264,600.00124,297View SEC Filing  
5/9/2016August J MorettiCFOSell5,000$18.00$90,000.0022,879View SEC Filing  
3/11/2016Thadd M VargasVPSell23,000$16.00$368,000.00137,737View SEC Filing  
12/3/2015August J. MorettiCFOSell15,000$18.11$271,650.0021,319View SEC Filing  
6/12/2015Thadd M VargasVPSell5,000$20.70$103,500.00View SEC Filing  
12/2/2014August J MorettiCFOSell5,339$15.85$84,623.15View SEC Filing  
12/2/2014James A SchoeneckCEOSell36,727$15.85$582,122.95View SEC Filing  
12/2/2014Thadd M VargasVPSell8,247$15.85$130,714.95View SEC Filing  
11/19/2014Matthew M GoslingVPSell71,000$15.36$1,090,560.00View SEC Filing  
3/14/2014James SchoeneckCEOSell17,000$14.54$247,180.00View SEC Filing  
3/14/2014Matthew GoslingVPSell21,875$14.74$322,437.5011,396View SEC Filing  
12/2/2013Michael Md SweeneyCMOSell4,270$8.40$35,868.009,084View SEC Filing  
12/2/2013Thadd VargasVPSell5,296$8.40$44,486.4061,698View SEC Filing  
5/10/2013James A SchoeneckCEOBuy25,000$5.11$127,750.00View SEC Filing  
3/6/2013Karen A DawesDirectorBuy2,000$5.96$11,920.00View SEC Filing  
8/14/2012Peter D StapleDirectorBuy5,000$5.01$25,050.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Depomed (NASDAQ DEPO) News Headlines

Source:
DateHeadline
Depomed (DEPO) versus Its Peers Critical ReviewDepomed (DEPO) versus Its Peers Critical Review
www.americanbankingnews.com - May 24 at 1:20 AM
BRIEF-Starboard Value Cuts Stake In Depomed Inc To 4.3 PctBRIEF-Starboard Value Cuts Stake In Depomed Inc To 4.3 Pct
www.reuters.com - May 23 at 8:41 AM
Depomed Inc (NASDAQ:DEPO) Is Trading At A 26% DiscountDepomed Inc (NASDAQ:DEPO) Is Trading At A 26% Discount
finance.yahoo.com - May 23 at 8:41 AM
The Jurys Still Out On DepomedThe Jury's Still Out On Depomed
seekingalpha.com - May 21 at 8:42 AM
Depomed (DEPO) Receives Consensus Rating of "Hold" from BrokeragesDepomed (DEPO) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 20 at 7:38 PM
Depomed (DEPO) SVP Matthew M. Gosling Sells 19,674 SharesDepomed (DEPO) SVP Matthew M. Gosling Sells 19,674 Shares
www.americanbankingnews.com - May 15 at 8:16 PM
BRIEF-Starboard Value Lp Reports 6.1 Pct Stake In Depomed Inc As Of May 10, 2018BRIEF-Starboard Value Lp Reports 6.1 Pct Stake In Depomed Inc As Of May 10, 2018
www.reuters.com - May 15 at 9:07 AM
Form 4 DEPOMED INC For: May 08 Filed by: FOGARTY JAMES PForm 4 DEPOMED INC For: May 08 Filed by: FOGARTY JAMES P
www.streetinsider.com - May 11 at 5:17 PM
Form 4 DEPOMED INC For: May 08 Filed by: STAPLE PETER DForm 4 DEPOMED INC For: May 08 Filed by: STAPLE PETER D
www.streetinsider.com - May 11 at 9:20 AM
Why Depomed Inc.s Shares Soared 23.2% HigherWhy Depomed Inc.'s Shares Soared 23.2% Higher
www.msn.com - May 11 at 9:20 AM
Why Depomed Inc.'s Shares Soared 23.2% HigherWhy Depomed Inc.'s Shares Soared 23.2% Higher
finance.yahoo.com - May 11 at 9:19 AM
Edited Transcript of DEPO earnings conference call or presentation 10-May-18 12:30pm GMTEdited Transcript of DEPO earnings conference call or presentation 10-May-18 12:30pm GMT
finance.yahoo.com - May 11 at 9:19 AM
 Analysts Anticipate Depomed (DEPO) Will Post Quarterly Sales of $62.48 Million Analysts Anticipate Depomed (DEPO) Will Post Quarterly Sales of $62.48 Million
www.americanbankingnews.com - May 11 at 1:46 AM
Depomeds (DEPO) CEO Arthur Higgins on Q1 2018 Results - Earnings Call TranscriptDepomed's (DEPO) CEO Arthur Higgins on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 5:21 PM
US STOCKS ON THE MOVE-Armo BioSciences, Synchronoss, DepomedUS STOCKS ON THE MOVE-Armo BioSciences, Synchronoss, Depomed
www.nasdaq.com - May 10 at 5:21 PM
Depomed: 1Q Earnings SnapshotDepomed: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 5:21 PM
Depomed (DEPO) Announces Quarterly  Earnings ResultsDepomed (DEPO) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 10 at 3:53 PM
Depomed up 21% on Q1 earnings beatDepomed up 21% on Q1 earnings beat
seekingalpha.com - May 10 at 11:28 AM
BRIEF-Depomed Q1 Earnings Per Share $0.48BRIEF-Depomed Q1 Earnings Per Share $0.48
www.reuters.com - May 10 at 8:57 AM
Earnings Reaction History: Depomed, Inc., 83.3% Follow-Through Indicator, 11.9% SensitiveEarnings Reaction History: Depomed, Inc., 83.3% Follow-Through Indicator, 11.9% Sensitive
www.nasdaq.com - May 10 at 8:57 AM
Depomed Inc. 2018 Q1 - Results - Earnings Call SlidesDepomed Inc. 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 10 at 8:57 AM
Depomed Earnings PreviewDepomed Earnings Preview
seekingalpha.com - May 10 at 8:57 AM
$0.14 EPS Expected for Depomed (DEPO) This Quarter$0.14 EPS Expected for Depomed (DEPO) This Quarter
www.americanbankingnews.com - May 9 at 11:20 PM
Depomed to Present at the UBS Global Healthcare ConferenceDepomed to Present at the UBS Global Healthcare Conference
finance.yahoo.com - May 7 at 8:46 AM
Depomed (DEPO) Downgraded by BidaskClub to "Sell"Depomed (DEPO) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - May 5 at 12:29 AM
Depomed to Report First-Quarter 2018 Financial Results on Thursday, May 10, 2018Depomed to Report First-Quarter 2018 Financial Results on Thursday, May 10, 2018
finance.yahoo.com - May 3 at 8:44 AM
Depomed (DEPO) to Release Quarterly Earnings on MondayDepomed (DEPO) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 7:23 AM
Depomed (DEPO) Given Average Rating of "Hold" by AnalystsDepomed (DEPO) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - April 25 at 7:30 PM
Depomed Announces the Appointment of John B. Thomas as Senior Vice President, Investor Relations and Corporate CommunicationsDepomed Announces the Appointment of John B. Thomas as Senior Vice President, Investor Relations and Corporate Communications
finance.yahoo.com - April 20 at 5:00 PM
Depomed (DEPO) Downgraded to "Sell" at BidaskClubDepomed (DEPO) Downgraded to "Sell" at BidaskClub
www.americanbankingnews.com - April 19 at 1:56 PM
Depomed Announces the Appointment of John B. Thomas as Senior Vice President, Investor Relations and Corporate ...Depomed Announces the Appointment of John B. Thomas as Senior Vice President, Investor Relations and Corporate ...
www.globenewswire.com - April 17 at 5:27 PM
Recent Analysis Shows Urban Outfitters, Depomed, Helios and Matheson Analytics, Keryx Biopharmaceuticals ...Recent Analysis Shows Urban Outfitters, Depomed, Helios and Matheson Analytics, Keryx Biopharmaceuticals ...
globenewswire.com - April 16 at 8:45 AM
Depomed (DEPO) Rating Lowered to Neutral at Janney Montgomery ScottDepomed (DEPO) Rating Lowered to Neutral at Janney Montgomery Scott
www.americanbankingnews.com - April 12 at 9:00 PM
Does Depomed Inc’s (NASDAQ:DEPO) Past Performance Indicate A Weaker Future?Does Depomed Inc’s (NASDAQ:DEPO) Past Performance Indicate A Weaker Future?
finance.yahoo.com - April 12 at 5:05 PM
Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com - April 9 at 8:59 AM
Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)  Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)  
finance.yahoo.com - April 9 at 8:59 AM
Piper Jaffray Analysts Give Depomed (DEPO) a $9.00 Price TargetPiper Jaffray Analysts Give Depomed (DEPO) a $9.00 Price Target
www.americanbankingnews.com - April 7 at 12:26 PM
Form 3 DEPOMED INC For: Apr 02 Filed by: Bukofzer StanForm 3 DEPOMED INC For: Apr 02 Filed by: Bukofzer Stan
www.streetinsider.com - April 5 at 10:52 AM
Depomed Sees Unusually High Options Volume (DEPO)Depomed Sees Unusually High Options Volume (DEPO)
www.americanbankingnews.com - April 5 at 6:30 AM
When Will Depomed Inc (NASDAQ:DEPO) Become Profitable?When Will Depomed Inc (NASDAQ:DEPO) Become Profitable?
finance.yahoo.com - April 3 at 5:04 PM
Depomed (DEPO) Names Stan Bukofzer, MD as Senior Vice President and Chief Medical and Scientific OfficerDepomed (DEPO) Names Stan Bukofzer, MD as Senior Vice President and Chief Medical and Scientific Officer
www.streetinsider.com - April 2 at 5:02 PM
Depomed Announces the Appointment of Stan Bukofzer, MD as Senior Vice President and Chief Medical and Scientific ...Depomed Announces the Appointment of Stan Bukofzer, MD as Senior Vice President and Chief Medical and Scientific ...
www.globenewswire.com - April 2 at 5:02 PM
Depomed Announces the Appointment of Stan Bukofzer, M.D. as Senior Vice President and Chief Medical and Scientific OfficerDepomed Announces the Appointment of Stan Bukofzer, M.D. as Senior Vice President and Chief Medical and Scientific Officer
finance.yahoo.com - April 2 at 5:02 PM
Depomed (DEPO) PT Lowered to $6.00Depomed (DEPO) PT Lowered to $6.00
www.americanbankingnews.com - April 1 at 11:24 AM
Depomed (DEPO) Receives Consensus Recommendation of "Hold" from BrokeragesDepomed (DEPO) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 31 at 7:46 PM
Depomed Distances Itself From NucyntaDepomed Distances Itself From Nucynta
seekingalpha.com - March 27 at 9:07 AM
Depomed (DEPO) Lowered to Sell at BidaskClubDepomed (DEPO) Lowered to Sell at BidaskClub
www.americanbankingnews.com - March 26 at 11:30 PM
Depomed (DEPO) Downgraded by ValuEngine to Strong SellDepomed (DEPO) Downgraded by ValuEngine to Strong Sell
www.americanbankingnews.com - March 25 at 6:58 PM
BidaskClub Downgrades Depomed (DEPO) to Strong SellBidaskClub Downgrades Depomed (DEPO) to Strong Sell
www.americanbankingnews.com - March 25 at 9:30 AM
Mizuho Reaffirms Buy Rating for Depomed (DEPO)Mizuho Reaffirms Buy Rating for Depomed (DEPO)
www.americanbankingnews.com - March 23 at 1:30 PM

SEC Filings

Depomed (NASDAQ:DEPO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Depomed (NASDAQ:DEPO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Depomed (NASDAQ DEPO) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.